Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
5:08
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
Non-Hodgkin Lymphoma Similar Videos
-
Risk stratification and therapy for high-grade NHL_Kristie Blum, MD; #DDHO2021
2:27
-
Ranjana Advani, MD; Stanford University #BtC_ASCO21
15:14
Dr. Ranjana Advani shares strategies for Integrating Recently Approved Therapies for B-cell NHL Into Practice.
-
Amitkumar Mehta, MD; University of Alabama at Birmingham O’Neal Comprehensive Cancer Center; 5Live #ASH21
8:55
Key insights from the 2021 Annual Hematology meeting in Atlanta